{"url_path":"/sec/cprx/8-k/2026-07-16/item-5-01","section_key":"item-5-01","section_title":"Item 5.01 Changes in Control of Registrant.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-304984-index.html","accession_number":"0001193125-26-304984","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-304984-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":81,"has_tables":true,"body_markdown":"Item 5.01 Changes in Control of Registrant.\n\nThe disclosures under the Introductory Note, Item 3.01, Item 3.03, Item 5.02 and Item 5.03 are incorporated herein by reference.\n\nAs a result of the consummation of the Merger, there was a change in control of the Company, and the Company became a wholly owned subsidiary of Parent.\n\nTo the knowledge of the Company, there are no arrangements which may at a subsequent date result in a further change in control of the Company."}